Akebia doses first patient in Phase 2 ebribafusp trial for rare complement-mediated kidney diseasesPUBT·2 days ago, 12:07 PMAKBA+1.64%
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney DiseasesUnusual Whales·2 days ago, 12:02 PMAKBA+1.64%
Akebia Therapeutics (NASDAQ:AKBA) Earns Buy Rating from Analysts at Westpark CapitalMarket Beat·Sep 8 at 03:42 PMAKBA+1.64%
Akebia Therapeutics holds investor meetings at Wells Fargo Healthcare ConferencePUBT·Sep 1 at 12:02 PMAKBA+1.64%
Small-Cap Tech and Biotech Firms Advance Commercialization as Partnerships and Pipelines Drive FocusGlobal Report·Sep 1 at 10:13 AMAPPS-4.75%AKBA+1.64%
The Biotech Reality Check: Breakthrough Trials and the Grind for SurvivalGlobal Report·Aug 29 at 10:11 AMAKBA+1.64%CLGN+2.35%
Piper Sandler Reaffirms Their Buy Rating on Akebia Therapeutics (AKBA)Tip Ranks·Aug 17 at 12:21 PMAKBA+1.64%
Akebia Q2 2026 earnings: Vafseo growth did not offset Auryxia declineTradingKey·Aug 5 at 09:21 PMAKBA+1.64%
Akebia Therapeutics (NASDAQ:AKBA) Releases Earnings ResultsMarket Beat·Aug 5 at 08:56 PMAKBA+1.64%STT-1.20%
AKBA: Vafseo's strong growth offset Auryxia's decline, but total revenues and net income fell year-over-yearQuartr·Aug 5 at 08:17 PMAKBA+1.64%
